Literature DB >> 7828281

Hypersensitivity and cross-reactivity to cisplatin and analogues.

A A Shlebak1, P I Clark, J A Green.   

Abstract

We report on a 49-year-old woman with relapsing ovarian cancer who developed a hypersensitivity reaction (HSR) to carboplatin and, subsequently, to cisplatin. This patient was known to be allergic to Co-Amoxiclav and talc, both giving rise to a transient macular skin rash, but had no other history of atopy. Similar cases, including some of life-threatening severity, have been reported in the literature. These severe reactions may prevent a small population of young patients from receiving effective therapy with cisplatin or its analogues, treatment known to be associated with a significant improvement in survival in germ-cell tumours, ovarian cancer and osteogenic sarcoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828281     DOI: 10.1007/BF00689458

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

Review 1.  Toxic effects of cis-dichlorodiammineplatinum(II) in man.

Authors:  D D Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

2.  No increase in allergic reactions with intracavitary administration of cisplatin.

Authors:  M Markman
Journal:  Lancet       Date:  1984-11-17       Impact factor: 79.321

3.  Anaphylactic reactions to repeated intravesical instillation with cisplatin.

Authors:  L Denis
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

4.  Positive direct antiglobulin test in a pediatric patient following high-dose cisplatin.

Authors:  G Cinollo; G Dini; E Franchini; E Lanino; F Sindaco; A Garaventa
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Anaphylactoid reaction to mannitol.

Authors:  J D Lamb; J A Keogh
Journal:  Can Anaesth Soc J       Date:  1979-09

6.  Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial.

Authors:  T Anderson; N Javadpour; R Schilsky; A Barlock; R C Young
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Phase I study of carboplatin (CBDCA) in children with cancer.

Authors:  D M Bacha; B Caparros-Sison; J A Allen; R Walker; C T Tan
Journal:  Cancer Treat Rep       Date:  1986-07

8.  Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP).

Authors:  P J Creaven; S Madajewicz; L Pendyala; A Mittelman; E Pontes; M Spaulding; S Arbuck; J Solomon
Journal:  Cancer Treat Rep       Date:  1983-09

9.  Cisplatin-induced nonimmunologic adsorption of immunoglobulin by red cells.

Authors:  G Zeger; L Smith; D McQuiston; D Goldfinger
Journal:  Transfusion       Date:  1988 Sep-Oct       Impact factor: 3.157

10.  Intravesical cisplatin for superficial bladder tumors.

Authors:  M S Blumenreich; B Needles; A Yagoda; P Sogani; H Grabstald; W F Whitmore
Journal:  Cancer       Date:  1982-09-01       Impact factor: 6.860

View more
  13 in total

Review 1.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

2.  A case of severe hepatotoxicity induced by cisplatin and 5-fluorouracil.

Authors:  Ayaka Yaegashi; Kensuke Yoshida; Naoto Suzuki; Izumi Shimada; Yusuke Tani; Yasuo Saijo; Akira Toyama
Journal:  Int Cancer Conf J       Date:  2019-11-19

3.  Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA.

Authors:  Semi Park; Stephen J Lippard
Journal:  Biochemistry       Date:  2011-02-28       Impact factor: 3.162

4.  Hypersensitivity reactions to carboplatin in children.

Authors:  Ilaria Lazzareschi; Antonio Ruggiero; Riccardo Riccardi; Giorgio Attinà; Cesare Colosimo; Anna Lasorella
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

5.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

6.  Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.

Authors:  Yoshihiro Shibata; Hiroshi Ariyama; Eishi Baba; Yasushi Takii; Taito Esaki; Kenji Mitsugi; Tanji Tsuchiya; Hitoshi Kusaba; Koichi Akashi; Shuji Nakano
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

7.  Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.

Authors:  Manojkumar Bupathi; Joud Hajjar; Stacie Bean; Siqing Fu; David Hong; Daniel Karp; Bettzy Stephen; Kenneth Hess; Funda Meric-Bernstam; Aung Naing
Journal:  Invest New Drugs       Date:  2016-09-29       Impact factor: 3.850

8.  [Basophil activation test as in vitro assay for cisplatin allergy].

Authors:  A Viardot-Helmer; H Ott; I Sauer; H F Merk
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

Review 9.  Prevention and management of antineoplastic-induced hypersensitivity reactions.

Authors:  K M Zanotti; M Markman
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

10.  A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.

Authors:  Patricia A Demoor; Yuri Matusov; Colleen Kelly; Shobha Kolan; Linda Barnachea; Lyudmila A Bazhenova
Journal:  J Cancer       Date:  2011-03-10       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.